Caristo wins FDA authorization for cardiovascular risk predictor

Caristo Diagnostics received FDA de novo authorization for CaRi-Heart, an AI tool that quantifies coronary inflammation to predict cardiovascular mortality risk over 10 years using routine coronary computed tomography angiography scans.

This Wire brief sits within Fusion42's coverage of Medtech.